30 closest matches · ranked by relevance
Microbicide Delivery System Acceptability
Primary: User Sensory Perception & Experience (USPE; Perceptibility) Scale Item Means — 3.64; 3.86; 4.35; 3.83 units on a scale
Microbicide Applicator
Primary: Number of Colposcopic Findings (Baseline and After One Week of Product Use) — 3; 0; 2; 0 colposcopic findings — p=0.4870
HIV Prevention
Primary: Acceptability of Future Product Use — 143; 132; 143; 56 Participants
HIV/AIDS
Primary: PrEP Adherence — 12; 4 Participants
HIV Infections
Primary: Self-reported Adherence to Each Regimen — 94; 93.8; 93.9 percentage of expected doses
HIV · Sexually Transmitted Infections (STI)
Primary: Frequency of Use — 1.14; 1.31; 0.00; 0.00 units on a scale
HIV
Primary: Number of Participants With High Adherence at Six Months — 36; 40 Participants
Microbicide Delivery System Perceptibility and Acceptability
Primary: User Sensory Perception & Experience (USPE; Perceptibility) Scale Item Means — 3.67; 3.29; 3.86; 3.42 units on a scale
HIV · Medication Adherence
Primary: Tel-me-box Adherence — 10; 16.5; 1.5; 7 days (out of 30)
HIV · Sexually Transmitted Diseases · Pre-exposure Prophylaxis
Primary: Acceptability: System Usability Scale — 75.76 score on a scale
Substance Abuse · HIV Infections
Primary: Feasibility: Proportion of Persons Screened Who Are Eligible and Enrolled — 30 Eligible persons screened who enrolled
HIV/AIDS · HIV Prevention
Primary: Tenofovir Diphosphate (TFV-DP) Concentration — 2441; 3472; 406 femtomole/million cells
Microbicide Delivery System Perceptibility and Acceptability
Primary: User Perception Scale Scores — 3.31; 3.36; 2.12; 2.62 units on a scale
HIV/AIDS · Substance Use Disorders · Adherence, Medication
Primary: Feasibility of Digital Pills to Measure PrEP Adherence — 411; 368; 320 Expected ingestions per pill counts
HIV
Primary: Safety: Grade 2 or Higher Adverse Events — 64; 61; 56 participants — p=0.88
Risk Reduction
Primary: Long-term Adherence Metrics Via Hair Concentrations of Tenofovir and Short-term Adherence Metric of Urine Concentrations of Tenofovir. — 33; 26; 31; 19 Participants
HIV
Primary: Retention in the Cohort — 88; 84; 87 Participants
Smoking
Primary: Change From Baseline Plasma Concentration of Nicotine/Cotinine After Each ad Libitum Use Session. — 1.7621; 2.4113; 1.9446; 5.5571 (ng/mL)
PSA · Unprotected Sex
Primary: Number of Female Participants With Positive PSA at 2-Month Visit — 18; 20 Participants
Healthy
Primary: Delivery System Success Rate (DSSR) — 66.67; 66.67; 100.00; 100.00 percentage of participants
Safety of Vaginal Film Use
Primary: Grade 2 or Higher Urogenital System Adverse Event Related to Film Use — 2 Participants
HIV
Primary: Mean Number of Returned Used Applicators Per Month (i.e in 30 Days) — 5.2; 5.7; 5.5; 5.8 Used gel applicators per month
Safety · Acceptability
Primary: Number of Participants That Successfully Insert Vaginal Film — 8; 8; 22; 22 Participants — p=>.99
Cervical Neoplasia
Primary: Sensitivity and Specificity — 0.86; 0.80 % of participants correctly diagnosed
Pharmacokinetics · Safety
Primary: Number of Participants With Grade 2 or Higher Adverse Events — 2; 5 Participants — p=.025
HIV
Primary: Actual Number of Study Visits Completed by 24 Weeks — 3.5927; 4.6263; 4.6374 Visits — p=0.6983
Human Papillomavirus Infection
Primary: Antibody Response to HPV Vaccine for HPV 6,11,16,18. — 1086.49; 1054.13; 745.06; 776.84 Milli Merck Units — p=>0.20
Medication Adherence
Primary: Medication Adherence — 88.1; 96.6; 94.4 percentage of doses taken (pill count)
HIV/AIDS · Adherence
Primary: Enacted Adherence as Measured by Electronic Monitoring at 6 and 24 Months — 40.2; 36.8; 27.0; 26.6 percentage of adherence
Human Immunodeficiency Virus
Primary: Number of Participants With Self-reported Self-administration of HIV Testing — 46; 44 Participants